ArticleEmerging microbes & infections2026
Receptor-binding specificity and antigenic properties of a genotype D1.1 A(H5N1) influenza virus isolated from a human.
Article in Emerging microbes & infections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- H5N1 influenza binding and cell entry via human class II MHC, and blocking by cross-reactive antibodies.bioRxiv : the preprint server for biology · 2026Article
- Contribution of E190D and Q226H Mutations in HA to the Receptor-Binding Profile of D1.1 Genotype H5N1 Viruses.Influenza and other respiratory viruses · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clade 2.3.4.4b A(H5N1) influenza viruses continue to expand their host range and pose increasing public health concerns. A case of severe human infection with genotype D1.1 A(H5N1) with HÀ substitutions was diagnosed in British Columbia. It is important to monitor receptor-binding specificity and antigenicity of emerging variants of circulating influenza A(H5N1) viruses. To evaluate potential human adaptation of this virus, we enriched HA-variant subpopulations and assessed sialic acid receptor usage via glycan microarray, solid-phase assays, and biolayer interferometry. All variants bound exclusively to avian-type sialic acid receptors. The antigenicity of the tested A(H5N1) variants was covered by candidate vaccine viruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.